Traws Reports Final Phase 2a Ratutrelvir Data, Plans FDA Talks on PAXLOVID-Ineligible Path
TRAW sits 15% above its 52-week low of $0.219 on light trading volume (0.3× avg).
Summary
Traws reported final Phase 2a results showing ratutrelvir resolved COVID symptoms in 13.5 days versus 14.5 for PAXLOVID with fewer treatment-related adverse events and no viral rebound, and said it will pursue an FDA registration path in PAXLOVID-ineligible patients. The TXM tablet bridging study and toxicology retest also completed, with regulatory resubmission planned for Q4 2026.
Key Events · Product Development and Regulatory · TRAW
-
Ratutrelvir Phase 2a Meets Competitive Bar
In 62 PAXLOVID-eligible subjects, median time to sustained symptom resolution was 13.5 days on ratutrelvir versus 14.5 days on PAXLOVID, with no viral rebound through Day 28.
-
Cleaner Tolerability Than PAXLOVID
Treatment-related adverse events occurred in 1 of 32 ratutrelvir patients versus 4 of 30 PAXLOVID patients; in the 30-subject PAXLOVID-ineligible cohort, symptoms resolved in 14.0 days with no treatment-related adverse events.
-
FDA Path Narrowed to Ineligible Patients
Traws will discuss a registration strategy focused on adults ineligible for PAXLOVID, including a potential adaptive Phase 2b/pivotal program and Fast Track designation.
-
TXM Tablet and Toxicology Cleared
The compressed tablet bridging study showed comparable exposure to powder-in-capsule, supporting once-monthly dosing; two rat Pig-a studies found no mutations up to 500 mg/kg, a margin of roughly 125-fold over planned clinical exposure, with regulatory resubmission planned for Q4 2026.
Analysis · TRAW · Life Sciences
The first hard clinical readout for ratutrelvir, the company's lead COVID asset, lands with competitive rather than decisive numbers: symptom resolution of 13.5 days versus 14.5 days for PAXLOVID, no viral rebound through Day 28, and just 1 of 32 treatment-related adverse events versus 4 of 30 on PAXLOVID. More consequential is the strategic detail — Traws will ask the FDA to build its registration path around patients who cannot take PAXLOVID, a smaller but underserved population with limited oral options, and will seek Fast Track plus a potential adaptive Phase 2b/pivotal design. That narrows the commercial claim but may shorten the path to approval. The TXM tablet bridging study and a clean toxicology retest remove a preclinical obstacle, with resubmission to regulators planned for Q4 2026. Against a going-concern warning and Nasdaq delisting risk previously disclosed in the Q2 10-Q, positive data supports the equity story but does not by itself fund the trials — the $50 million Roth equity line disclosed 2026-10-23 remains the financing backstop, and a reverse split of 1-for-8 to 1-for-15 goes to a shareholder vote on December 3, 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRAW was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.22 to $3.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.